Related News

No related news articles were found.

parabolic drugs ltd (PDL) Related Businessweek News

No Related Businessweek News Found

parabolic drugs ltd (PDL) Details

Parabolic Drugs Limited develops and manufactures active pharmaceutical ingredients (API) and API intermediates. The company offers oral and sterile semi synthetic penicillin APIs; and oral and sterile cephalosporin APIs in antibiotic area, as well as non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company markets its products in approximately 50 countries, primarily including the Middle East, the United Kingdom, Africa, China, Korea, Japan, the European Union, Latin America, the United States, and ASEAN. Parabolic Drugs Limited was founded in 1996 and is headquartered in Chandigarh, India.

parabolic drugs ltd (PDL) Key Developments

Parabolic Drugs Ltd. Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015 and Consolidated Earnings Results for the Year Ended March 31, 2015

May 19 15

Parabolic Drugs Ltd. announced audited standalone earnings results for the fourth quarter and year ended March 31, 2015 and consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 266.1 million against INR 1,120.5 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 923.3 million against INR 941.1 million a year ago. Loss from ordinary activities before tax was INR 1,352.2 million against INR 1,176.6 million a year ago. Net loss was INR 2,885.9 million or INR 46.63 per basic and diluted share before & after extraordinary items against INR 610.1 million or INR 9.86 per basic and diluted share before & after extraordinary items a year ago.
For the year, on standalone basis, the company reported net sales/income from operations of INR 2,287.8 million against INR 4,303.8 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 1,503.1 million against INR 1,369.5 million a year ago. Loss from ordinary activities before tax was INR 2,490.0 million against INR 2,200.2 million a year ago. Net loss was INR 3,793.2 million or INR 61.29 per basic and diluted share before & after extraordinary items against INR 1,317.4 million or INR 21.29 per basic and diluted share before & after extraordinary items a year ago.
For the year, on consolidated basis, the company reported net sales/income from operations of INR 2,403.0 million against INR 4,467.0 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 1,511.6 million against INR 1,383.9 million a year ago. Loss from ordinary activities before tax was INR 2,501.5 million against INR 2,220.9 million a year ago. Net loss was INR 3,804.7 million or INR 61.48 per basic and diluted share before & after extraordinary items against INR 1,338.1 million or INR 21.62 per basic and diluted share before & after extraordinary items a year ago.

Parabolic Drugs Ltd., Board Meeting, May 18, 2015

May 5 15

Parabolic Drugs Ltd., Board Meeting, May 18, 2015. Agenda: To consider and approve the audited financial results for the quarter and the year ended on March 31, 2015.

Parabolic Drugs Ltd. to Report Q4, 2015 Results on May 18, 2015

May 5 15

Parabolic Drugs Ltd. announced that they will report Q4, 2015 results on May 18, 2015

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.